Recombinant Flu Vaccine May Protect Seniors Better than Traditional Vaccine

Over 9,000 individuals, ≥50 years old took part in the trial
Over 9,000 individuals, ≥50 years old took part in the trial

Protein Sciences announced the publication of new clinical data in the New England Journal of Medicine that compared Flublok Quadrivalent vs. a traditional egg-based quadrivalent inactivated vaccine. 

The efficacy trial randomized ~9,000 people aged ≥50 years to receive either Flublok Quadrivalent or a traditional quadrivalent vaccine. Patients administered Flublok Quadrivalent demonstrated a 40% reduced risk of developing culture-confirmed influenza. These findings meet both pre-specified criteria for non-inferiority as well as superiority of Flublok vs. the traditional egg-based quadrivalent inactivated vaccine. 

Lisa Dunkle, MD, Chief Medical Officer of Protein Sciences, added, "We demonstrated statistically significantly better protection by Flublok based on considerably fewer people contracting the flu after vaccination with Flublok Quadrivalent." 

Related Articles

Flublok Quadrivalent, approved by the Food and Drug Administration (FDA) in October 2016, is a recombinant protein-based vaccine developed without the use of eggs. It contains three times more active ingredients than traditional vaccines and its high antigen content makes it optimal for older adults or those who are immunocompromised. 

Flublok does not contain influenza virus, antibiotics, formaldehyde, preservatives, egg protein, latex, gluten or gelatin. It will be available in prefilled syringes in time for the upcoming flu season.

For more information call (800) 488-7099 or visit Flublok.com.